NCT00758134终止2 期
Prospective Phase II Trial Evaluating Efficacy of Trastuzumab Therapy in HER2 FISH Positive and/or HER2 Mutation Positive, Pretreated, Non-Small Cell Lung Cancer Patients (MO20509)
Armando Santoro, MD1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2008年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Response rate
研究概览
简要总结
This is a prospective study assessing efficacy of trastuzumab therapy in pretreated NSCLC patients. Patients with locally advanced or metastatic NSCLC, HER2 FISH positive and/or with HER2 gene mutation, pretreated with at least one previous chemotherapy line will be considered eligible for the trial. After evaluation of inclusion and exclusion criteria, and after signature of informed consensus form, all eligible patients will receive trastuzumab 6 mg/kg every 3 weeks (8 mg/kg loading dose) until disease progression, unacceptable toxicity or patient refusal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •• Histologically confirmed diagnosis of NSCLC. Availability of tumor tissue for HER2 FISH analysis and/or HER2 gene mutation analysis is mandatory
- •Stage IIIB (with effusion) or stage IV or disease relapsed after surgery or radiotherapy and in any case not suitable for radiotherapy or surgery with curative intent
- •HER2 FISH positive defined as high polysomy or gene amplification, or presence of HER2 gene mutation in exon 20
- •At least one measurable lesion
- •Patients pretreated with at least one chemotherapy regimen. Previous therapy with erlotinib or other tyrosine kinase inhibitors is allowed.
- •Patients compliance to trial procedures
- •Age ≥ 18 years
- •Written informed consent
- •Adequate BM function (ANC ≥1.5x109/L, Platelets ≥100x109/L, HgB >9 g/dl)
- •Adequate liver function (bilirubin <G2, transaminases no more than 3xULN/<5xULN in present of liver metastases).
- •Normal level of alkaline phosphatase and creatinine
- •If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of approved contraceptive method [intrauterine contraceptive device (IUD), birth control pills, or barrier device] during and for three months after trial.
- •ECOG performance status 0-1 and life expectancy of at least 3 months
- •Have recovered from the acute, reversible effects of prior surgery or radiotherapy. This means that at least 3 weeks should have elapsed since prior radiotherapy.
排除标准
- •• HER2 FISH negative tumor and no evidence of HER2 gene mutation in exon 20
- •Concomitant radiotherapy
- •Untreated brain metastases or leptomeningeal disease involvement.
- •All disease sites previously included in radiotherapy fields. If all sites were included in radiotherapy fields patient is eligible only if there is evidence of progressive disease after completion of radiotherapy.
- •No measurable lesion
- •Left ventricular ejection fraction (FEV) <50%
- •Diagnosis of any other malignancy during the last 5 years, except for in situ carcinoma of cervix uteri and squamous cell carcinoma of the skin
- •Any previous HER2 blocking therapy. Previous therapy with anti EGFR agents is allowed
- •Pregnancy or lactating
- •Other serious illness or medical condition including: Congestive heart failure (NYHA class II, III, IV) or history of documented congestive heart failure, unstable angina pectoris, myocardial infarction in the last 12 months, poorly controlled hypertension (systolic >180 mmHg or diastolic >100 mmHg), clinically significant valvular heart disease, or high-risk uncontrolled arrhythmias. Patients with dyspnoea at rest due to malignant or other disease (e.g. pulmonary metastases with lymphangitis) or who require supportive oxygen therapy. Active serious uncontrolled infections. Poorly controlled diabetes mellitus
- •Treatment with any investigational drug within 30 days before the beginning of treatment with study drug.
研究组 & 干预措施
A
Experimental
Trastuzumab 6 mg/Kg
干预措施: Trastuzumab (Herceptin) (Drug)
结局指标
主要结局
Response rate
时间窗: every two months
次要结局
- Time to disease progression, overall survival, safety and assessment of biomarkers potentially implicated in trastuzumab sensitivity/resistance(every two months)
研究者
Armando Santoro, MD
MD
Istituto Clinico Humanitas
研究点 (1)
Loading locations...
相似试验
招募中
2 期
TRUDI: TDXD+Durva in HER2+/Low IBCInflammatory Breast Cancer Stage IIIHER2-positive Breast CancerHER2 Low Breast AdenocarcinomaInvasive Breast CancerBreast CancerNCT05795101Filipa Lynce, MD63
已完成
2 期
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast CancerHER2 AmplifiedHuman Epidermal Growth Factor Receptor 2 (HER2)Advanced Breast CancerNCT02091960Astellas Pharma Global Development, Inc.103
尚未招募
2 期
Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine NeoplasmsPancreatic Neuroendocrine NeoplasmNCT05316480Fudan University42
已完成
2 期
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOXMetastatic or Recurrent Gastric AdenocarcinomaHer-2 Positive Gastric CancerNCT01396707Asan Medical Center55
已完成
2 期
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)Breast CancerNCT01853748Dana-Farber Cancer Institute512